GeneDx Holdings Corp. $WGS Shares Sold by Deutsche Bank AG

Deutsche Bank AG lessened its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 5.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 9,846 shares of the company’s stock after selling 529 shares during the quarter. Deutsche Bank AG’s holdings in GeneDx were worth $872,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of WGS. Lazard Asset Management LLC acquired a new position in GeneDx during the 4th quarter valued at about $35,000. GAMMA Investing LLC grew its stake in shares of GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock worth $39,000 after purchasing an additional 264 shares during the last quarter. Comerica Bank bought a new stake in shares of GeneDx in the 4th quarter worth approximately $50,000. US Bancorp DE increased its holdings in shares of GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after buying an additional 548 shares in the last quarter. Finally, Quarry LP bought a new position in shares of GeneDx in the fourth quarter valued at $78,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Insider Activity at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 5,278 shares of GeneDx stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total value of $490,854.00. Following the completion of the sale, the chief financial officer directly owned 3,392 shares in the company, valued at $315,456. The trade was a 60.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Katherine Stueland sold 9,657 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $90.94, for a total transaction of $878,207.58. Following the transaction, the chief executive officer owned 4,940 shares in the company, valued at approximately $449,243.60. This trade represents a 66.16% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 522,411 shares of company stock valued at $62,535,051. 29.60% of the stock is currently owned by corporate insiders.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $128.66 on Monday. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. GeneDx Holdings Corp. has a 1 year low of $28.86 and a 1 year high of $130.33. The business has a fifty day simple moving average of $93.85 and a 200 day simple moving average of $87.67. The firm has a market cap of $3.70 billion, a price-to-earnings ratio of 2,573.20 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The firm had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on WGS shares. Guggenheim reaffirmed a “buy” rating and set a $115.00 target price (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wells Fargo & Company raised their price objective on shares of GeneDx from $78.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Piper Sandler set a $120.00 price objective on shares of GeneDx and gave the stock an “overweight” rating in a research report on Monday, August 4th. Wall Street Zen upgraded GeneDx from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, Jefferies Financial Group upgraded GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a report on Friday, May 9th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $101.63.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.